Research Studies

Alzheimer buttonThe Wake Forest School of Medicine Alzheimer’s Disease Core Center offers patients a chance to participate  in clinical trials that may impede the development of mild cognitive impairment or Alzheimer’s disease and help the functioning of the aging brain.

   


CURRENTLY RECRUITING

Therapeutic Effects of Intranasally-administered Insulin in Adults with Mild Cognitive Impairment or Mild Alzheimer’s Disease (INI Study)

This 18-month study investigates whether a type of insulin (Humulin® R) improves memory when administered intranasally (as a “nasal spray”) to adults with a mild memory impairment or early Alzheimer’s disease. 
Learn more...

 

Anti-amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4 Study)

This 36-month study is testing an investigational drug in older people who have evidence of elevated amyloid build-up in their brains, but who do not yet show symptoms of Alzheimer’s disease.
Learn more...

 

Alzheimer’s Disease Clinical Core (ADCC)

The Alzheimer’s Disease Prevention Participant Repository is an observational study that will be used to identify and characterize early risk factors that predict memory decline and dementia in adults, with or without early signs of memory impairment. 
Learn more...

 

Study of Nasal Insulin to Fight Forgetfulness – Short-Acting Insulin Aspart – 12 weeks (SNIFF-QUICK Study)

The purpose of this three-month research study is to find out whether insulin aspart improves memory when administered as a spray into the nasal passages of adults with mild memory impairment or early Alzheimer’s disease. 
Learn more...

 

Brain Energy And Memory Study (BEAM)

The purpose of this 24-week research study is to find out how adults with abnormal insulin sensitivity and those with memory/thinking problems respond to different diets. 
Learn more...

 

A Phase 2a Multi-Center Study of 18F-FDG PET, Safety and Tolerability of AZD0530 in Mild Alzheimer’s Disease (FYN Connect Study)

The purpose of this research study is to determine whether AZD0530 is safe and effective in slowing decline in brain metabolism, memory and daily function in people Alzheimer’s disease (AD).
Learn more...

 

Apathy in Dementia Methylphenidate Trial 2 (ADMET II)

This 6 month study investigates the efficacy of methylphenidate for the treatment of clinically significant apathy in participants with Alzheimer’s disease.
Learn more...

 

AVID 18F-AV-1451: A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology (AVID)

Pictures of the brain made using the study drug during the life of study participants will be compared to results of brain autopsy after death.
Learn more...

 

EMERGE Study / Biogen 221AD302 - A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease 

The purpose of the study is to find out whether aducanumab has the potential to be a helpful treatment that slows down disease progression in subjects with early Alzheimer’s Disease (AD) by comparing it to placebo and to evaluate its safety (side effects), and to find out more about aducanumab. About 1350 people from150 research sites world-wide between 50 and 85 years old will take part in this 18 month study.


 Alzheimer's Steadfast Study / A Phase 3 Multi-Center, Randomized, Double Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of TTP-488 in Patients with Mild Alzheimer’s Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine

The purpose of this research study is to determine whether an investigational drug, azeliragon (TTP488) is safe and beneficial in delaying or altering the decline in memory and daily functioning when given to people with mild Alzheimer’s disease (AD). In this study, participants will be given either active study drug, azeliragon or placebo.  A total of 800 people at least 50 years old, have mild Alzheimer's Disease (AD) and are experiencing memory problems will take part in this study. Participants must be currently taking a cholinesterase inhibitor (such as donepezil, Aricept, rivastigmine, Exelon, galantamine or Razadyne) and/or memantine for the treatment of AD.

  

EXERT Study / Phase 3 Multi-Center Study of Therapeutic Effects of Exercise in Adults with Amnestic Mild Cognitive Impairment

The EXERT study will examine the effects of aerobic exercise on cognition, functional status, brain atrophy and blood flow, and cerebrospinal fluid biomarkers of Alzheimer’s disease in 300 adults with amnestic Mild Cognitive Impairment.  Adults will be between 65 and 89 years old. Participants will be randomized to one of two interventions: supervised and structured moderate/high intensity aerobic training vs.stretching/balance control for 12 months, followed by a 6-month unsupervised extension.

 


UPCOMING STUDIES

 


RECRUITMENT CLOSED

ADNI-2: Alzheimer’s Disease Neuroimaging Initiative 2 – Recruitment closed

ADNI 2 builds upon the successes of earlier ADNI phases to identify the earliest signs of AD and will help define the subtle changes that may take place in the brains of older people many years before overt symptoms of the disease appear.  
Learn more...

Noble-TCAD Study - Recruitment closed

The purpose of this research study is to evaluate whether an investigational drug (T-817MA) is safe and beneficial in delaying or altering the decline in memory and daily function when given to people with mild to moderate Alzheimer’s disease.
Learn more...

 


 

 

Last Updated: 09-29-2016
Comprehensive Cancer Centers National Designation is RenewedMagnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.